Швейцарская компания ten23 health получила разрешение на производство препаратов на основе малых интерферирующих РНК

Making more than chocolate: Swiss CDMO gets go-ahead to make siRNAs Biotech company ten23 health recently obtained GMP certifications to begin making advanced medicines. August 12, 2026 Earlier this month, Swiss-based contract development and manufacturing organization (CDMO) ten23 health announced GMP certification to manufacture advanced therapy medicinal products (ATMPs). Authorization is included for oligonucleotide products including siRNA, mRNA, and antisense oligonucleotides (ASOs). Production is set to take place across its two facilities in Basel and Visp, both based in Switzerland. “Obtaining ATMP licenses for both Basel and Visp reinforces our commitment to enabling sterile medicines for next-generation therapeutics,” ten23 CEO Hanns-Christian Mahler said in a public release. “We are proud to provide our partners with integrated, high-quality sterile product solutions that accelerate their molecule’s journey from drug substance to drug products.” According to the company, a manufacturing deal for its first oligonucleotide program is already underway. Although the company did not disclose the client, it said that it is “advancing further into clinical development.” ten23 health also publicized a new research collaboration with DSM-Firmenich in mid-July. The partnership with the Dutch and Swiss-based chemical company is set to focus on innovating new excipients for biological drug formulations. Both the Visp and Basel facilities appear to be well-equipped for the manufacturing of ATMPs. According to ten23 health, the Basel site can provide small-scale support for early- to late-phase production, while the Visp facility allows for late-stage scaling and commercial manufacturing. ten23 health isn’t the only company focusing on siRNAs and other advanced therapies. Earlier this year, Ribo Life Science and Madrigal Pharmaceuticals agreed on a $60 million partnership to develop six siRNA programs. Meanwhile, academic labs and biotech companies are demonstrating the promise of mixed-modality approaches, for example, using siRNA-antibody conjugates to treat rare genetic diseases such as myotonic dystrophy. An increase in clinical success has led analysts to estimate the oligonucleotide CDMO market will reach almost $10 billion by 2031. Demand appears to be increasing for the commercial scale-up and quality control of an array of RNA medicines, particularly ASOs and siRNA pipelines. TIDES Europe Nov 3, 2026 TO Nov 5, 2026 |Amsterdam, Netherlands Europe's largest and most comprehensive oligonucleotide and peptide therapeutics event featuring scientific breakthroughs, manufacturing innovations, and regulatory insights. Access new data & case studies from world-renowned speakers and companies across the entire landscape of oligos, peptides, mRNA, drug delivery and partnering strategies.